Posted on Leave a comment

Have you heard of Tere’s inspiring diabetic story?

“My Doctor told me I have less than a year to live if I won’t let them amputate my leg, but I didn’t let them . . . here’s how I am still alive now!”

 

When doctors initially told 60-year-old Theresa “Tere” Schaufer that she had diabetes, she went into denial for 20 years.

“I was diagnosed with diabetes 20 years ago, and only when my doctor told me that they needed to cut my leg, did I realize that my diabetes was serious,” she says.

A major contributing factor

“Doctors told me the only way to survive this fight was to amputate my leg,” Schaufer says.  

 

She acknowledges that she had lived an unhealthy lifestyle for many years. Working in a restaurant as a cashier, she did very little exercise, ate fast food and drank sodas on a regular basis.

“If the doctor tells you you’re a diabetic, don’t ignore it. You have to know why foot care is important for someone with diabetes. Don’t get to where I am. The sooner you accept things, the better it is for your health.”

Only after her doctor advised amputation did she realize the seriousness of her situation. Schaufer’s lifestyle had a hugely negative impact on controlling her diabetes

 

It was very painful!

Schaufer had puss from underneath her foot and necrotic toe. “After the doctor examined my foot, it was like decaying,” she says. “I couldn’t handle the pain. It was excruciating!” She was given less than a year to live because of her poor lifestyle.

 

I started to accept the situation.

Schaufer finally accepted her fate as a diabetic after the doctor told her that her leg would have to be amputated.

 

“I saw it coming. The pain was terrible. I could no longer handle it. At this point I was prepared; whatever came had to be.”

 

Unexpected turn of events

“I was browsing a support page I found on the web and read about a colleague’s experience with the microcirculation therapy she had tried. She noted that it had an amazing effect on her diabetic foot ulcer,” Schaufer says.

 

Right there on the support page, the woman raved, “There is this new technology you can buy online, D’OXYVA, which was voted one of the Top 10 Diabetes Care Solution Providers 2018! I didn’t have to amputate my leg because of this amazing product. In just four weeks, I can see my diabetic foot ulcer improving!”

 

“I read these words, and it gave me the hope I’d been praying for,” noted Schaufer.

She only had a month before her scheduled amputation, and without hesitation, she used the remaining days to try out D’OXYVA. She ordered the product online and closely collaborated with their in-house support.

 

“I was under D’OXYVA therapy for one month, taking it twice a day, once in the morning and once before bed as advised. It was very easy to use and non-invasive. In the first few days, I was skeptical as I wasn’t seeing any improvements, but I continued anyway and followed their suggested therapy guide,” Schaufer explains.

Thankful for D’OXYVA

When it was time for her to go back to her doctor and give her consent to amputate, her doctor was shocked to see her leg.

“What happened?” Those were the exact words my doctor asked upon seeing my leg after only a month. “Your wounds seemed to be healing from the inside,” my doctor said.

After a thorough check-up and the usual diagnostic check of my foot’s PI (perfusion index), he said the words that I never expected to hear. “We don’t need to amputate your leg anymore, but you need to continue whatever you’ve been doing for the past month.”

I then introduced him to D’OXYVA, and he was amazed by how this product had saved me.

 



Helping others

“I’m on my third month of D’OXYVA therapy, and it does amazing things for my health! I don’t think I have thanked D’OXYVA enough for this chance to live longer. I wouldn’t have the outlook on life that I have now,” Schaufer continues cheerfully. 
  

She is now also leading a healthy life. “This changed how I live my life, and I will continue sharing my experience as much as I can to help others.”

 

Schaufer often spends time with other “to-be-amputees” struggling to deal with their situation. “God gave me my situation to help others,” she maintains.

One of the ladies she counselled remarked how Schaufer had helped her tremendously. “She told me that I gave her her life back,” Schaufer says, breaking into tears.

“I’m in a way thankful for what I have been through with my diabetes because, without it, I wouldn’t have stumbled across my strength and my ability to help others.”

Posted on Leave a comment

Patients are transforming from passive recipients of healthcare services to active participants in their own health

This is a preview of a research report from Business Insider Intelligence, Business Insider’s premium research service. To learn more about Business Insider Intelligence, click here. Current subscribers can read the report here.

The consumerization of healthcare — a fundamental shift in patients’ preferences, behaviors, and demands around healthcare services — is threatening hospitals’ bottom lines. For the first time, patients are transforming from passive recipients of healthcare services to active participants in their own health. They’re flocking to online review sites to choose which doctor to see, skipping hospital visits in favor of a health clinic in their local CVS, and aren’t afraid to ditch providers that don’t offer them an engaging experience.

The superior customer service expectations of millennials, declines in hospital profitability, and threats from startup providers and retail pharmacies intensify the need for providers to revamp the patient experience. Providers’ current engagement capabilities are weak, and deficiencies around scheduling, appointment wait times, and billing are dragging on patient satisfaction, driving patients elsewhere and draining provider revenue.

In The Healthcare Consumerization ReportBusiness Insider Intelligence explores the trends that are driving providers to revamp their care services. We then outline how patients’ expectations for transparency, convenience, and access are transforming the way they interact with providers across each stage of care. Finally, we detail strategies health systems and hospitals can implement to create a consumer-centric patient experience that fosters satisfaction, loyalty, and patient volume.

The companies mentioned in this report are: 98point6, BayCare, Cleveland Clinic, CVS, Integris, Kaiser Permanente, Luma Health, New York-Presbyterian, One Medical, Publix, Target, Walgreens, Walmart, Yelp, and Zocdoc.

Here are some of the key takeaways from the report:

  • The consumerization of healthcare is redefining how consumers engage with providers across each stage of care.
  • But the vast majority of healthcare providers haven’t sufficiently altered their services to align with current patient expectations. Only 8% of US hospitals and health systems demonstrate strong consumer-centric performance, per a 2018 Kaufman Hall survey.
  • Failure to react to patient preferences hurts provider organizations’ bottom lines. US hospital profit margins are already thinning, and an emerging reimbursement model that ties a portion of providers’ compensation to patient satisfaction means providers can’t afford to preserve the status quo.
  • Alternative players with consumer-focused healthcare services threaten to poach patients from traditional health systems. Tech-focused primary care startups, like One Medical and 98point6, and retail outlets, like Target, Walmart, and CVS, offer patients on-demand access to healthcare providers via mobile apps and convenient locations to receive healthcare services, drawing them away from incumbent health systems.
  • In order to retain patients — and keep them from straying to alternative care services — providers must transform their services with an emphasis on transparency, access, and ongoing engagement outside of the clinic.
  • Healthcare providers that tailor their services to the new healthcare consumer will be well positioned to see growth. Alternatively, businesses that don’t implement these changes could find themselves falling behind the rest of the industry or closing their doors for good.

In full, the report:

  • Details how patient behavior, preferences, and expectations have changed.
  • Outlines the demographic and industry trends that should add a sense of urgency for providers to revamp the patient experience.
  • Summarizes how the patient experience providers currently offer isn’t conducive to loyalty and is likely driving patients to nonhospital services.
  • Explains strategies health systems and hospitals can implement to create a consumer-centric patient experience that fosters satisfaction, loyalty, and patient volume.
  • Offers examples of provider organizations that have successfully adopted new strategies to encourage patient-doctor communication, improve satisfaction, and drive scheduling capacity.

Reference: https://www.businessinsider.com/the-healthcare-consumerization-report-2018-11?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed:+businessinsider+%28Business+Insider%29

Posted on Leave a comment

Apple Watch 4 can detect D’OXYVA’s benefits.

Did you recently buy yourself a Christmas gift?

Would it happen to be the new Apple Watch Series 4? If so, did you know you can use it to detect D’OXYVA’s benefits?

D’OXYVA is the only fully non-invasive, completely painless, transdermal (over-the-skin) microcirculatory solution that has been clinically tested to significantly improve microcirculation.
The improvement of microcirculation, i.e., blood flow to the smallest blood vessels, benefits your health, your immune system and your overall sense of well-being in a variety of ways.

D’OXYVA® plays a vital role in regulating and creating homeostasis (stability) in the autonomic nervous system (ANS) or, more precisely, between its main two functions, the sympathetic and parasympathetic nerve activities.

D’OXYVA® has been shown to achieve this by stimulating parasympathetic nerve activities that are responsible for “rest and digest” functions, reducing heart rate, blood pressure, calming, regenerating, healing, and energy reservation.

About Apple Watch 4
One of the biggest upgrades to the Apple Watch Series 4 from its predecessor is its ability to record an electrocardiogram and detect issues with how the user’s heart is functioning. The company’s FDA-approved feature is now live for users in the US.

The device can detect irregularities in your heartbeat, which can point to critical conditions like atrial fibrillation that may result in a stroke. If your Watch classifies your rhythm as a high heart rate or atrial fibrillation, you’ll want to talk to your doctor.

However, it’s worth noting that the Watch only records a basic single-lead ECG, so it can’t detect a stroke, heart attack, or other heart conditions like the 12-lead ECGs taken at a doctor’s office.

If you’re using a Watch Series 4 in the US, here’s how you can take an ECG:

• Ensure your device is updated to watch OS 5.1.2 and paired with an iPhone 5s or later with iOS 12.1.1 on board.

• Set up the ECG app by opening Apple Health on your device and following the on-screen instructions. A prompt should show up automatically, but if you don’t see it, head to Health Data > Heart > Electrocardiogram (ECG).

• Wear your Watch 4 with a snug fit on the wrist you’ve specified in the Apple Watch app (you can find or change this in the Apple Watch app; tap the My Watch tab, then head to General > Watch Orientation).

• Launch the ECG app on your Watch.

• Rest your arms comfortably on a table or in your lap.

• Hold your finger on the Digital Crown without pressing down for 30 seconds. You’ll then see your results and any symptoms that the device detects.
Tap Save to record your symptoms.

• To review your ECG, open the Health app on your iPhone and head to the Health Data tab. Then, tap Heart > Electrocardiogram (ECG), and tap the ECG. You’ll find an option to export a PDF of it, which you can share with your doctor.

References:
https://www.msn.com/en-us/news/technology/apple-wa…
https://www.doxyva.com/kb_results.asp?ID=64

Posted on Leave a comment

Foot blood flow, polyneuropathy and foot ulceration in diabetes mellitus.

Corbin DO1, Young RJ, Morrison DC, Hoskins P, McDicken WN, Housley E, Clarke BF.
Peripheral Vascular Clinic, Royal Infirmary, Edinburgh, Scotland.


Comparable groups of diabetic patients asymptomatic of neuropathy (Group A), with chronic painful polyneuropathy (Group B) and painless polyneuropathy causing recurrent foot ulceration (Group C) were studied for differences in pedal blood flow, peripheral somatic and autonomic neuropathy and vascular calcification.

Blood flow abnormalities detected by doppler waveform analysis and consistent with reduced peripheral vascular resistance were found in all three diabetic patient groups. The abnormalities were of similar severity in Groups A and B but generally more marked in Group C. Test results of peripheral somatic nerve function became progressively more abnormal from Group A to Group C. Autonomic neuropathy was equally severe in Groups B and C, although mild abnormalities were recorded in diabetic patients asymptomatic of neuropathy.

A similar pattern was seen for vascular calcification in the tarsal and metatarsal arteries: marked in both neuropathic groups (B and C) but mild in Group A. It was concluded that abnormal blood flow consistent with reduced peripheral vascular resistance is very common in the feet of diabetic patients, whether or not they are symptomatic of neuropathy, and is most severe in those with chronic painless polyneuropathy and recurrent foot ulceration. No clear relationship was found between autonomic nerve dysfunction and the degree of blood flow abnormality.

HOW CAN D’OXYVA HELP?

Clinical studies with D’OXYVA®  (deoxyhemoglobin vasodilator) have shown extraordinary results for the role of transdermal noninvasive wound care and significant improvement of blood flow using ultra-purified, nontoxic, FDA-cleared molecules, such as CO2especially when all other approaches failed.

In an ongoing multiyear, multi-country, multicenter, randomized clinical trial on patients with diabetic foot ulcers, D’OXYVA has demonstrated speeding up diabetic wound healing and ultimately wound closure to an average of 5 weeks**.

Posted on 4 Comments

Circularity Healthcare Named “Company of the Year” – Top 10 Diabetes Care Solution Providers 2018

Circularity Healthcare Named “Company of the Year” – Top 10 Diabetes Care Solution Providers 2018

BREAKING NEW GROUNDS IN DIABETES CARE

According to the American Diabetes Association, millions of people around the world live with diabetes or know someone living with diabetes. No type of diabetes is curable yet; however, it is a very treatable disease, and no matter how frightening, annoying, and frustrating it can be, people with diabetes can live long, healthy, and happy lives. Our goal is to provide you the information, tools, and resources to help make that happen.

In a recent statistics report from CDC National Diabetes Statistics, diabetes remains the 7th leading cause of death in the United States in 2015, with 79,535 death certificates listing it as the underlying cause of death and a total of 252,806 death certificates listing diabetes as an underlying or contributing cause of death.

With numerous methods on the market for managing and treating diabetes, there is one product that is a cut above the others when it comes to diabetes care–D’OXYVA by Circularity Healthcare. Setting a new paradigm in health science, D’OXYVA is a truly unique technology at its core, a first-of-its-kind biotech solution clinically validated to significantly lower the risk of diabetes and cardiovascular complications.

Circularity Healthcare was recently selected for the list of Top 10 Diabetes Care Solution Providers of 2018 in the upcoming November Diabetes Carespecial edition of MedTech Outlook magazine after receiving more than 270 unique nominations from more than 39,000 qualified print and 66,000 qualified digital subscribers. The magazine does not rank the top ten providers; it lists them in alphabetical order on a full page. In addition, the magazine will run a featured article on Circularity and its D’OXYVA product line in the same special edition this November.

The future holds favorable prospects for Circularity Healthcare. They are expecting continued commercial growth with D’OXYVA, with other major announcements to follow shortly in multiple leading media outlets in the US and around the world as Circularity’s global marketing and PR campaign based on years of yetunpublished highly successful clinical evidence unfolds in the coming weeks and months.

At the end of it all, D’OXYVA is indeed a revolutionary and a much-needed step toward a powerful and safe diabetes care solution that is adding immeasurable value to health outcomes.

December 2018 digital issue of MedTech Outlook: https://www.medicaltechoutlook.com/magazines/December2018/Diabetes_Care 

ABOUT D’OXYVA

Clinical studies with D’OXYVA®  (deoxyhemoglobin vasodilator) have shown extraordinary results for the role of transdermal noninvasive wound care using ultra-purified, nontoxic, FDA-cleared molecules, such as CO2especially when all other approaches failed.

In an ongoing multiyear, multi-country, multicenter, randomized clinical trial on patients with diabetic foot ulcers, D’OXYVA has demonstrated speeding up diabetic wound healing and ultimately wound closure to an average of 5 weeks**.